Our lab conducts translational oncology research through early stage clinical studies inspired by nanotechnologies, systems biology, and biomarker driven therapies. We focus on solid tumors with an emphasis on highly lethal subtypes such as ovarian cancers. We subscribe to both “high-tech” and “low-tech” theranostic approaches that leverage innovative advances within CSB. To date, these efforts have generated traction both domestically and abroad. We are currently establishing a comprehensive multi-departmental program to prospectively profile gynecologic cancers including multi-omics (sequencing, proteomics, liquid biopsies), pathology (digital and multiplexed profiling), imaging and clinical phenotypes. We seek to ultimately advance cancer theranostics by better understanding the spatiotemporal evolution of cancers and uncovering novel treatment response readouts using integrated machine learning and statistical inferences. Our work has been externally funded by the National Cancer Institute, Robert Wood Johnson Foundation, V Foundation for Cancer Research, Ovarian Cancer Research Fund, and the Department of Defense.
Batool SM, Hsia T, Beecroft A, Lewis B, Ekanayake E, Rosenfeld Y, Escobedo AK, Gamblin AS, Rawal S, Cote RJ, Watson M, Wong DTW, Patel AA, Skog J, Papadopoulos N, Bettegowda C, Castro CM, Lee H, Srivastava S, Carter BS, Balaj L Extrinsic and intrinsic preanalytical variables affecting liquid biopsy in cancer. Cell Rep Med. 2023;4(10):101196 - PMID: 37725979 - PMCID: PMC10591035 - DOI: 10.1016/j.xcrm.2023.101196
Batool SM, Yekula A, Khanna P, Hsia T, Gamblin AS, Ekanayake E, Escobedo AK, You DG, Castro CM, Im H, Kilic T, Garlin MA, Skog J, Dinulescu DM, Dudley J, Agrawal N, Cheng J, Abtin F, Aberle DR, Chia D, Elashoff D, Grognan T, Krysan K, Oh SS, Strom C, Tu M, Wei F, Xian RR, Skates SJ, Zhang DY, Trinh T, Watson M, Aft R, Rawal S, Agarwal A, Kesmodel SB, Yang C, Shen C, Hochberg FH, Wong DTW, Patel AA, Papadopoulos N, Bettegowda C, Cote RJ, Srivastava S, Lee H, Carter BS, Balaj L The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring. Cell Rep Med. 2023;4(10):101198 - PMID: 37716353 - PMCID: PMC10591039 - DOI: 10.1016/j.xcrm.2023.101198
Jo A, Green A, Medina JE, Iyer S, Ohman AW, McCarthy ET, Reinhardt F, Gerton T, Demehin D, Mishra R, Kolin DL, Zheng H, Cheon J, Crum CP, Weinberg RA, Rueda BR, Castro CM, Dinulescu DM, Lee H Inaugurating High-Throughput Profiling of Extracellular Vesicles for Earlier Ovarian Cancer Detection. Adv Sci (Weinh). 2023;10(27):e2301930 - PMID: 37485618 - PMCID: PMC10520636 - DOI: 10.1002/advs.202301930
Hong JS, Son T, Castro CM, Im H CRISPR/Cas13a-Based MicroRNA Detection in Tumor-Derived Extracellular Vesicles. Adv Sci (Weinh). 2023;10(24):e2301766 - PMID: 37340600 - PMCID: PMC10460892 - DOI: 10.1002/advs.202301766
Silberman JN, Bercow AS, Gockley AA, Eisenhauer EL, Sisodia R, Randall T, Del Carmen MG, Goodman A, Castro CM, Melamed A, Bregar AJ Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States. Gynecol Oncol. 2023;175:60-65 - PMID: 37327540 - DOI: 10.1016/j.ygyno.2023.06.001
- More publications ...